^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Endometrial Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Endometrial carcinoma: Preferred regimens…Carboplatin/paclitaxel/trastuzumab (for stage III/IV or recurrent HER2-positive uterine serous carcinoma)
    Secondary therapy:
    carboplatin + paclitaxel
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Gastroesophageal Junction Adenocarcinoma)
    New
    Excerpt:
    Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anticancer treatment for their metastatic disease.
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

    Excerpt:
    Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease….Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    10.1200/JCO.2017.76.5966
    Trial ID:
    NCT01367002